Institutional
Foresite Capital Management VI LLC
CIK 0002013341
$460.3M
Reported AUM
17
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · Foresite Capital Management VI LLC · Q1 2026
AI · grounded in 13F
Foresite Capital Management VI LLC closed its position in RAPT Therapeutics, Inc. RAPT, reducing exposure by $52.9M. The fund also exited its holdings in Natera, Inc. NTRA for $15.4M and Atai Beckley N.V. ATAI for $11.2M. Offsetting these sales, the fund established new positions in Minerva Neurosciences, Inc. NERV for $11.9M and Celldex Therapeutics, Inc. CLDX for $10M. Additionally, the fund increased its share count in Corvus Pharmaceuticals, Inc. CRVS by 32.6%.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Ticker | Issuer | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|
| 1 | CGON | CG Oncology, Inc. | $150.3M | 32.67% | — | HELD |
| 2 | ALMS | ALUMIS INC. | $93.6M | 20.33% | — | HELD |
| 3 | CNTA | Centessa Pharmaceuticals plc | $54.2M | 11.77% | — | HELD |
| 4 | CRVS | Corvus Pharmaceuticals, Inc. | $26.8M | 5.82% | +450,000 | +32.6% |
| 5 | DNLI | Denali Therapeutics Inc. | $23.2M | 5.05% | +209,971 | +21.0% |
| 6 | AGIO | AGIOS PHARMACEUTICALS, INC. | $17.8M | 3.86% | -5,000 | -0.9% |
| 7 | VSTM | Verastem, Inc. | $16.7M | 3.62% | +11,511 | +0.4% |
| 8 | KYMR | Kymera Therapeutics, Inc. | $12.2M | 2.65% | — | HELD |
| 9 | NERV | Minerva Neurosciences, Inc. | $12.0M | 2.60% | +1,986,600 | NEW |
| 10 | CLDX | Celldex Therapeutics, Inc. | $10.0M | 2.18% | +315,913 | NEW |
| 11 | ATAI | AtaiBeckley Inc. | $9.7M | 2.12% | +2,750,000 | NEW |
| 12 | HNGE | Hinge Health, Inc. | $8.5M | 1.85% | +85,400 | +63.3% |
| 13 | CRNX | Crinetics Pharmaceuticals, Inc. | $7.7M | 1.67% | +212,010 | NEW |
| 14 | OKUR | OnKure Therapeutics, Inc. | $6.0M | 1.30% | +1,445,783 | NEW |
| 15 | JBIO | Jade Biosciences, Inc. | $4.5M | 0.98% | +320,000 | NEW |
| 16 | GHRS | GH Research PLC | $4.4M | 0.96% | +315,492 | NEW |
| 17 | ZURA | Zura Bio Ltd | $2.7M | 0.58% | +450,000 | NEW |
| 18 | RAPT | RAPT Therapeutics, Inc. | — | — | -1,562,500 | EXITED |
| 19 | NTRA | Natera, Inc. | — | — | -67,356 | EXITED |
| 20 | ATAI | Atai Beckley N.V. | — | — | -2,750,000 | EXITED |
Source: SEC EDGAR · accession 0001104659-26-062467. 13F discloses long positions only — shorts, foreign equities, and options are excluded.